TR201904903T4 - Alternatif tamamlama yolağının C3 ve C5 konvertazının proteaz aktivitesinin ölçülmesine yönelik bir yöntem. - Google Patents

Alternatif tamamlama yolağının C3 ve C5 konvertazının proteaz aktivitesinin ölçülmesine yönelik bir yöntem. Download PDF

Info

Publication number
TR201904903T4
TR201904903T4 TR2019/04903T TR201904903T TR201904903T4 TR 201904903 T4 TR201904903 T4 TR 201904903T4 TR 2019/04903 T TR2019/04903 T TR 2019/04903T TR 201904903 T TR201904903 T TR 201904903T TR 201904903 T4 TR201904903 T4 TR 201904903T4
Authority
TR
Turkey
Prior art keywords
convertase
complement pathway
alternative complement
measuring
protease activity
Prior art date
Application number
TR2019/04903T
Other languages
English (en)
Inventor
Johnson Krista
Forbes Christen
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of TR201904903T4 publication Critical patent/TR201904903T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/25—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving enzymes not classifiable in groups C12Q1/26 - C12Q1/66
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/50—Other enzymatic activities
    • C12Q2521/537—Protease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a

Abstract

Alternatif tamamlama yolağının bir konvertazının proteaz aktivitesinin ölçülmesine yönelik bir yöntem sağlanır. Yöntem tipik olarak, bir biyotin bağlama proteini ile kaplanmış bir katı faz üzerinde bir biyotinlenmiş C3b'nin immobilize edilmesini içerir. Alternatif tamamlama yolağının büyük ölçüde homojen bileşenleri, bir konvertaz oluşturmak üzere bir serumdan arındırılmış ve jelatinden arındırılmış tampon içinde immobilize edilmiş C3b ile inkübe edilebilir. Konvertazın aktivitesi genel olarak bir immünoanaliz ile ölçülür.
TR2019/04903T 2015-03-25 2016-03-28 Alternatif tamamlama yolağının C3 ve C5 konvertazının proteaz aktivitesinin ölçülmesine yönelik bir yöntem. TR201904903T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562138235P 2015-03-25 2015-03-25

Publications (1)

Publication Number Publication Date
TR201904903T4 true TR201904903T4 (tr) 2019-05-21

Family

ID=55795010

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/04903T TR201904903T4 (tr) 2015-03-25 2016-03-28 Alternatif tamamlama yolağının C3 ve C5 konvertazının proteaz aktivitesinin ölçülmesine yönelik bir yöntem.

Country Status (5)

Country Link
US (2) US20180087087A1 (tr)
EP (1) EP3274468B1 (tr)
ES (1) ES2721781T3 (tr)
TR (1) TR201904903T4 (tr)
WO (1) WO2016151557A1 (tr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3775900A1 (en) * 2018-03-26 2021-02-17 Alexion Pharmaceuticals, Inc. High throughput method for measuring the protease activity of complement c3 convertase

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4582810A (en) 1983-09-30 1986-04-15 Becton, Dickinson And Company Immuno-agglutination particle suspensions
DE3640412A1 (de) 1986-11-26 1988-06-09 Boehringer Mannheim Gmbh Verfahren zur bestimmung einer spezifisch bindefaehigen substanz
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
CA2102401A1 (en) 1992-06-09 1993-12-10 Friedrich Hoppe Latch and lockset system
PT1498427E (pt) 1992-08-21 2010-03-22 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6221657B1 (en) 1995-09-08 2001-04-24 Imutran Limited Modified human C3 DNA sequences and vectors
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
CA2722378C (en) 1996-12-03 2015-02-03 Amgen Fremont Inc. Human antibodies that bind tnf.alpha.
DE19724787A1 (de) 1997-06-06 1998-12-10 Biotez Berlin Buch Gmbh Bioche Streptavidin/Avidin beschichtete Oberflächen
US7255858B2 (en) 2001-08-10 2007-08-14 University Of Virginia Patent Foundation Enhancing the efficacy of immunotherapies by supplementing with complement
US7063946B2 (en) 2001-09-10 2006-06-20 Meso Scale Technologies, Llc. Methods, reagents, kits and apparatus for protein function analysis
AU2003293562A1 (en) 2002-12-26 2004-07-22 Meso Scale Technologies, Llc Methods, compositions and kits for biomarker extraction
US7319525B2 (en) 2003-11-06 2008-01-15 Fortebio, Inc. Fiber-optic assay apparatus based on phase-shift interferometry
CN101970002B (zh) 2007-08-27 2016-05-18 诺福麦德治疗学股份有限公司 用因子Bb特异性抗体抑制补体活化的方法
KR20110079705A (ko) 2008-09-30 2011-07-07 제넨테크, 인크. 림포톡신 길항제에 대한 류마티스 관절염 반응을 예측하는 생물학적 마커
WO2011085057A2 (en) 2010-01-06 2011-07-14 The Regents Of The University Of Colorado, A Body Corporate Methods for detecting insulin autoantibody
ES2552954T3 (es) 2010-04-30 2015-12-03 Alexion Pharmaceuticals, Inc. Anticuerpos anti-C5a y métodos para el uso de los anticuerpos

Also Published As

Publication number Publication date
EP3274468A1 (en) 2018-01-31
US20230265481A1 (en) 2023-08-24
ES2721781T3 (es) 2019-08-05
EP3274468B1 (en) 2019-02-20
WO2016151557A1 (en) 2016-09-29
US20180087087A1 (en) 2018-03-29

Similar Documents

Publication Publication Date Title
TWD198720S (zh) 項鍊
TWD196206S (zh) 手錶
NI201500103A (es) Anticuerpos cd47 que no agotan plaquetas ni glóbulos rojos y métodos de uso de los mismos.
MX2019014265A (es) Tratamientos conjuntos triples con anticuerpos.
UY37758A (es) Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
BR112014019331A8 (pt) anticorpos para cd47 e métodos de uso desses
TR201904997T4 (tr) Modifikasyona bağlı aktivite tahlilleri.
BR112015022602A2 (pt) composições compreendendo compostos de tienopirimidina e tienopiridina e métodos de uso dos mesmos
CR20170251A (es) Anticuerpos anti-c5 y métodos para su uso
CO6721041A2 (es) Anticuerpo anti-pcsk9 y métodos de uso
CL2015000582A1 (es) Anticuerpos anti-mcam y métodos asociados de uso
MA38632A1 (fr) Anticorps anti-récepteur de transferrine et procédés d'utilisation
AR094403A1 (es) Terapia de combinación de anticuerpos anti-her3
EA201591817A1 (ru) Не содержащая сыворотки среда для культивирования клеток
TWD196204S (zh) 錶
BR112018068843A2 (pt) método de comunicação entre dispositivos, e dispositivo entre dispositivos
AR114789A1 (es) Anticuerpos anti-hla-g y uso de los mismos
BR112015017099A2 (pt) transmissão de sinal de referência a partir de múltiplas células em modo suspenso
MX2016006743A (es) Ensayo de puente a base de resonancia de plasmon superficial para determinar la actividad biologica de moleculas multiespecificas multivalentes.
AR119997A1 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso
EA201992027A1 (ru) Водный состав антитела против pd-l1
EA202190237A1 (ru) Способы уменьшения мешающего влияния мишени лекарственного средства в иммунологическом анализе на антитела к лекарственному средству (ada)
EA201300126A1 (ru) Способ повышения активности активированной-потенцированной формы антител
MX2016005854A (es) Anticuerpo anti-her3 alosterico de la neuregulina.
ES2721935T3 (es) Anticuerpos anti-BAG3 para uso terapéutico